Malignant Mesothelioma Market - Global Forecast 2026-2032

The malignant mesothelioma market is advancing rapidly, shaped by new treatment modalities, evolving clinical pathways, and increasing operational and regulatory complexity. Senior decision-makers must stay ahead of multifaceted challenges and opportunities as care dynamics, commercialization strategies, and policy considerations shift in real time across regions.

Market Snapshot: Malignant Mesothelioma Market Growth and Trends

The malignant mesothelioma market grew from USD 905.16 million in 2025 to USD 986.67 million in 2026 and is projected to reach USD 1.60 billion by 2032, reflecting an expected CAGR of 8.54%. This trajectory demonstrates robust demand for novel therapeutics and strategic market transformation driven by significant clinical, scientific, and regulatory developments.

Scope & Segmentation

Treatment Modalities: Includes chemotherapy, immunotherapy, surgery, radiotherapy, and targeted therapies. Approaches range from established regimens to new immune checkpoint inhibitors and targeted agents that disrupt tumor biology.
Drug Classes: Covers antifolates, immune checkpoint inhibitors (CTLA-4, PD-1, PD-L1), kinase inhibitors, monoclonal antibodies, and platinum compounds, with each class informing trial design and value messaging.
Lines of Therapy: Encompasses first, second, and third-line settings. Early lines are characterized by broad clinical expectations, while later stages prioritize efficacy signals and unmet-need justification.
Administration Routes: Incorporates intraperitoneal, intravenous, and oral delivery, shaping patient experience, adherence, and health-system strategies.
Care Settings: Distribution across ambulatory surgical centers, hospitals, and specialty clinics guides commercialization planning and provider engagement initiatives.
Regions: Analyzes market dynamics and access across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting unique regulatory, payer, and infrastructure environments.

Key Takeaways: Strategic Insights for Malignant Mesothelioma Market Stakeholders

Therapeutic approaches have shifted from single-modality treatments to multidisciplinary, biomarker-driven strategies, underlining the clinical complexity and need for adaptive pathways.
Innovative immune checkpoint and mesothelin-targeted therapies now drive competitive differentiation, requiring robust clinical data and new paradigms for response assessment.
Stakeholders must navigate changing reimbursement expectations as payers emphasize durable benefits, real-world effectiveness, and manageable safety profiles in decision-making.
Integrated care models and specialist center networks are contributing to improved coordination, streamlined clinical trial enrollment, and accelerated adoption of advanced therapies.
Segmentation by drug class, therapy line, and administration route demands precise alignment across development, regulatory, and commercial teams to optimize launch success and market access.

Tariff Impact: Operational and Supply Chain Shifts in Oncology Therapeutics

Recent U.S. tariff adjustments in 2025 reshaped procurement and supply strategies for oncology treatments, including those for malignant mesothelioma. These changes drove manufacturers and health systems to assess local sourcing, diversify supplier networks, and prioritize scenario planning for commercial launches. The impact on supply chain resilience and total cost management has prompted a focus on value communication and operational flexibility.

Methodology & Data Sources

Analysis draws on a mixed-methods approach, combining structured primary interviews with key clinical, regulatory, and procurement experts and critical review of peer-reviewed literature, policy guidance, and company disclosures. Iterative cross-validation ensured accuracy, minimizing bias through evidence triangulation and scenario-based assessments.

Why This Report Matters

Enables decision-makers to anticipate critical clinical, operational, and regulatory shifts shaping the malignant mesothelioma market.
Delivers actionable segmentation insights to guide targeted development, pragmatic trial design, and tailored commercialization strategies across key regions.
Supports strategic planning by aligning biomarker-driven evidence, supply chain resilience, and payer requirements for sustainable market access.

Conclusion

Aligning scientific innovation, operational resilience, and strategic market access is essential for stakeholders navigating the evolving malignant mesothelioma landscape. Adoption of integrated, evidence-based approaches will support improved patient outcomes and sustained growth.

Additional Product Information:

Purchase of this report includes 1 year online access with quarterly updates.
This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Porter’s Five Forces Analysis
4.4. PESTLE Analysis
4.5. Market Outlook
4.5.1. Near-Term Market Outlook (0-2 Years)
4.5.2. Medium-Term Market Outlook (3-5 Years)
4.5.3. Long-Term Market Outlook (5-10 Years)
4.6. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025
7. Cumulative Impact of Artificial Intelligence 2025

8. Malignant Mesothelioma Market, by Treatment Type

8.1. Chemotherapy
8.1.1. Pemetrexed Combinations
8.1.2. Platinum Monotherapy
8.2. Immunotherapy
8.2.1. Ctla-4 Inhibitors
8.2.2. Pd-1 Inhibitors
8.3. Radiotherapy
8.4. Surgery
8.5. Targeted Therapy
8.5.1. Egfr Inhibitors
8.5.2. Mesothelin Targeted Agents
8.5.3. Vegf Inhibitors

9. Malignant Mesothelioma Market, by Drug Class

9.1. Antifolates
9.2. Immune Checkpoint Inhibitors
9.2.1. Ctla-4 Inhibitors
9.2.2. Pd-1 Inhibitors
9.2.3. Pd-l1 Inhibitors
9.3. Kinase Inhibitors
9.4. Monoclonal Antibodies
9.5. Platinum Compounds

10. Malignant Mesothelioma Market, by Line Of Therapy

10.1. First Line
10.2. Second Line
10.3. Third Line And Beyond

11. Malignant Mesothelioma Market, by Route Of Administration

11.1. Intraperitoneal
11.2. Intravenous
11.3. Oral

12. Malignant Mesothelioma Market, by End User

12.1. Ambulatory Surgical Centers
12.2. Hospitals
12.3. Specialty Clinics

13. Malignant Mesothelioma Market, by Region

13.1. Americas
13.1.1. North America
13.1.2. Latin America
13.2. Europe, Middle East & Africa
13.2.1. Europe
13.2.2. Middle East
13.2.3. Africa
13.3. Asia-Pacific

14. Malignant Mesothelioma Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Malignant Mesothelioma Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. United States Malignant Mesothelioma Market
17. China Malignant Mesothelioma Market

18. Competitive Landscape

18.1. Market Concentration Analysis, 2025
18.1.1. Concentration Ratio (CR)
18.1.2. Herfindahl Hirschman Index (HHI)
18.2. Recent Developments & Impact Analysis, 2025
18.3. Product Portfolio Analysis, 2025
18.4. Benchmarking Analysis, 2025
18.5. AbbVie Inc.
18.6. Advanz Pharma Corp.
18.7. Argenx SE
18.8. AstraZeneca Plc.
18.9. Boehringer Ingelheim GmbH
18.10. Bristol-Myers Squibb Company
18.11. Cipla Limited
18.12. Dr. Reddy's Laboratories
18.13. Eisai Co., Ltd.
18.14. Eli Lilly and Company
18.15. Emcure Pharmaceuticals Limited
18.16. F. Hoffmann-La Roche Ltd.
18.17. Fresenius Kabi AG
18.18. Karyopharm Therapeutics Inc.
18.19. Merck & Co., Inc.
18.20. Mylan N.V.
18.21. Nichi-Iko Pharmaceutical Co., Ltd
18.22. Novartis AG
18.23. Novocure GmbH
18.24. Ono Pharmaceutical Co. Ltd
18.25. Pfizer Inc.
18.26. Polaris Pharmaceuticals, Inc.
18.27. Sanofi S.A.
18.28. Sun Pharmaceuticals Industries Ltd
18.29. Wellona Pharma

List of Figures

FIGURE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET, FPNV POSITIONING MATRIX, 2025
FIGURE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
FIGURE 13. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)

List of Tables

TABLE 1. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 2. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 3. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 4. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 5. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 6. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 7. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY REGION, 2018-2032 (USD MILLION)
TABLE 8. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 9. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PEMETREXED COMBINATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 10. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 11. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 12. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 13. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 14. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 15. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 16. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 17. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 18. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 19. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 20. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 21. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 22. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 23. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 24. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 25. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 26. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY REGION, 2018-2032 (USD MILLION)
TABLE 27. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 28. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 29. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
TABLE 30. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
TABLE 31. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 32. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 33. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 34. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 35. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 36. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY REGION, 2018-2032 (USD MILLION)
TABLE 37. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 38. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MESOTHELIN TARGETED AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 39. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 40. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 41. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 42. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 43. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY REGION, 2018-2032 (USD MILLION)
TABLE 44. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 45. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ANTIFOLATES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 46. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 47. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 48. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 49. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 50. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 51. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 52. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY CTLA-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 53. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 54. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 55. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 56. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 57. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 58. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PD-L1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 59. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
TABLE 60. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 61. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY KINASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 62. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
TABLE 63. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
TABLE 64. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 65. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY REGION, 2018-2032 (USD MILLION)
TABLE 66. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 67. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY PLATINUM COMPOUNDS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 68. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 69. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 70. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 71. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 72. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
TABLE 73. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 74. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 75. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
TABLE 76. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
TABLE 77. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY THIRD LINE AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 78. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 79. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 80. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 81. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAPERITONEAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 82. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
TABLE 83. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 84. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 85. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
TABLE 86. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
TABLE 87. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 88. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 89. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
TABLE 90. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 91. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 92. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
TABLE 93. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 94. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 95. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
TABLE 96. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
TABLE 97. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 98. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
TABLE 99. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 100. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 101. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 102. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 103. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 104. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 105. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 106. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 107. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 108. AMERICAS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 109. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 110. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 111. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 112. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 113. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 114. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 115. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 116. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 117. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 118. NORTH AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 119. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 120. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 121. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 122. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 123. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 124. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 125. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 126. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 127. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 128. LATIN AMERICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 139. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 140. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 141. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 142. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 143. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 144. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 145. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 146. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 147. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 148. EUROPE MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 149. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 150. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 151. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 152. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 153. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 154. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 155. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 156. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 157. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 158. MIDDLE EAST MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 159. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 160. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 161. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 162. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 163. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 164. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 165. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 166. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 167. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 168. AFRICA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 169. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 170. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 171. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 172. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 173. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 174. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 175. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 176. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 177. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 178. ASIA-PACIFIC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 179. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
TABLE 180. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 181. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 182. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 183. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 184. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 185. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 186. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 187. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 188. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 189. ASEAN MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 190. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 191. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 192. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 193. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 194. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 195. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 196. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 197. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 198. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 199. GCC MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 200. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 201. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 202. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 203. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 204. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 210. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 211. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 212. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 213. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 214. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 215. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 216. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 217. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 218. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 219. BRICS MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 220. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 221. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 222. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 223. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 224. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 225. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 226. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 227. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 228. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 229. G7 MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 230. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 231. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 232. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 233. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 234. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 235. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 236. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 237. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 238. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 239. NATO MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 240. GLOBAL MALIGNANT MESOTHELIOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
TABLE 241. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 242. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 243. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 244. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 245. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 246. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 247. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 248. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 249. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 250. UNITED STATES MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
TABLE 251. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, 2018-2032 (USD MILLION)
TABLE 252. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
TABLE 253. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY CHEMOTHERAPY, 2018-2032 (USD MILLION)
TABLE 254. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
TABLE 255. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY TARGETED THERAPY, 2018-2032 (USD MILLION)
TABLE 256. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
TABLE 257. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, 2018-2032 (USD MILLION)
TABLE 258. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
TABLE 259. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
TABLE 260. CHINA MALIGNANT MESOTHELIOMA MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)

Companies Mentioned

The key companies profiled in this Malignant Mesothelioma market report include:

AbbVie Inc.
Advanz Pharma Corp.
Argenx SE
AstraZeneca Plc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cipla Limited
Dr. Reddy's Laboratories
Eisai Co., Ltd.
Eli Lilly and Company
Emcure Pharmaceuticals Limited
F. Hoffmann-La Roche Ltd.
Fresenius Kabi AG
Karyopharm Therapeutics Inc.
Merck & Co., Inc.
Mylan N.V.
Nichi-Iko Pharmaceutical Co., Ltd
Novartis AG
Novocure GmbH
Ono Pharmaceutical Co. Ltd
Pfizer Inc.
Polaris Pharmaceuticals, Inc.
Sanofi S.A.
Sun Pharmaceuticals Industries Ltd
Wellona Pharma

Table Information

Report Attribute	Details
No. of Pages	196
Published	January 2026
Forecast Period	2026 - 2032
Estimated Market Value ( USD ) in 2026	$ 986.67 Million
Forecasted Market Value ( USD ) by 2032	$ 1600 Million
Compound Annual Growth Rate	8.5%
Regions Covered	Global
No. of Companies Mentioned	26

License	Properties	Price
SINGLE USER LICENSE PDF, Excel and Online Access	This is a single user license, allowing one user access to the product.	€3505EUR$3,939USD£3,044GBP
1 - 5 USER LICENSE PDF, Excel and Online Access	This is a 1-5 user license, allowing up to five users have access to the product.	€3781EUR$4,249USD£3,283GBP
SITE LICENSE PDF, Excel and Online Access	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5125EUR$5,759USD£4,450GBP
ENTERPRISE LICENSE PDF, Excel and Online Access	This is an enterprise license, allowing all employees within your organization access to the product.	€6201EUR$6,969USD£5,385GBP

Market Snapshot: Malignant Mesothelioma Market Growth and Trends

Scope & Segmentation

Key Takeaways: Strategic Insights for Malignant Mesothelioma Market Stakeholders

Tariff Impact: Operational and Supply Chain Shifts in Oncology Therapeutics

Methodology & Data Sources

Why This Report Matters

Conclusion

Table of Contents

Companies Mentioned

Table Information

Related Topics

Related Reports

Malignant Mesothelioma Market Report 2025

Malignant Mesothelioma Drug Pipeline Analysis Report 2025

Malignant Mesothelioma - Global Strategic Business Report

Mesothelioma Drug Pipeline Analysis Report 2025

Mesothelioma - Pipeline Insight, 2025